Haleon PLC

Regulatory Filings • Feb 7, 2023

National Storage Mechanism | Additional information

RNS Number : 1556P

Haleon PLC

07 February 2023

Haleon plc concludes tender for statutory audit

7 February 2023: In its prospectus published June 2022, Haleon plc (the "Company") (LSE/NYSE: HLN) advised that it expected to conduct an audit tender process for the audit of the Company's financial statements for the year ending 31 December 2023, which would be subject to shareholder approval at the Company's 2023 Annual General Meeting (AGM).

Following the conclusion of a competitive tender process and recommendation from the Company's Audit and Risk Committee, the Board has approved the proposed appointment of KPMG LLP as its statutory auditor following completion of the audit of its accounts for the year ending 31 December 2022.  This appointment will be recommended to shareholders for approval at the 2023 AGM.

The Company would like to thank Deloitte LLP for their significant contribution during their time as the Company's auditors, including their work supporting the demerger and listing of Haleon as an independent consumer health company. Subject to shareholder approval at the 2023 AGM, we look forward to working with KPMG LLP.

Ends

Contacts

Media         Zoë Bird                +44 7736 746167

Investors   Sonya Ghobrial      +44 7392 784784

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding. 

For more information, please visit www.haleon.com.       

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPSSWSUWEDSEFE